1966153-17-2

1966153-17-2 structure

Name: C-Type Natriuretic Peptide (CNP) (1-22), human TFA
Chemical Name: C-Type Natriuretic Peptide (CNP) (1-22), human TFA
CAS Number: 1966153-17-2
Molecular Formula: C₉₅H₁₅₈F₃N₂₇O₃₀S₃
Molecular Weight: 2311.62
Catalog: Research Areas Cardiovascular Disease
Create Date: 2022-03-01 23:39:55
Modify Date: 2024-01-12 16:58:33
C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor[1][2][3].

Name	C-Type Natriuretic Peptide (CNP) (1-22), human TFA

Description	C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor[1][2][3].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease Research Areas >> Neurological Disease
Target	NPR-B
In Vitro	C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) (0.01, 0.1, 1, 10, 100, 1000 nM) increases cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner[1]. PK parameters of CNP immunoreactivity after a single intravenous administration of C-Type Natriuretic Peptide (CNP) (1-22), human (TFA)[1]: Dose (nM/kg) AUC0→∞ (pM・min/mL) MRT0→∞ (min) T1/2 (min) CLtot (mL/min/kg) Vdss (mL/kg) 20 320±54 1.02±0.18 1.42±0.45 63.9±11.9 64.2±5.1 PK parameters of CNP immunoreactivity after a single subcutaneous administration of C-Type Natriuretic Peptide (CNP) (1-22), human (TFA)[1]: Dose (nM/kg) Cmax (pM/mL) Tmax (min) AUC0→∞ (pM・min/mL) MRT0→∞ (min) T1/2 (min) BA (%) 50 9.02±3.74 5.0±0.0 152±73 13.9±3.4 10.0±5.0 19±9 Each value represents the mean±SD of 3 rats. MRT=mean residence time, CLtot=total clearance, T1/2=half-life period, BA=bioavailability. i.c.v. administration of C-Type Natriuretic Peptide (CNP) (1-22) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide[3].
References	[1]. Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680. [2]. Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24.

Molecular Formula	C₉₅H₁₅₈F₃N₂₇O₃₀S₃
Molecular Weight	2311.62

1966153-17-2	127869-51-6
141294-77-1	142878-79-3
33017-11-7	41475-27-8
1815618-06-4	1802078-41-6
57327-90-9	134374-28-0
1158522-08-7	2275217-85-9
940364-43-2	134104-43-1
131615-57-1	6906-52-1
930439-75-1	1018584-77-4
2764731-02-2	1375289-11-4